| GPA | IPF | Normal | ||
| Active | Remission | |||
| Patients n | 19 | 7 | 20 | 6 |
| Males | 52 | 42 | 77 | 33 |
| Age yrs | 56.6±28.25 | 51.0±18.8 | 70±18.8 | 45±13.8 |
| Smoking | ||||
| Never-/ex-/current smokers n | 11/13/1 | 3/3/0 | 3/20/3 | 2/3/1 21 |
| Pack-yrs | 10.1±24.3 | 6.8±14.0 | 30±26.2 | |
| FVC % pred | 113.0±23.5 | 108.5±26.0 | 69.5±27.8 | NA |
| TL,CO % pred | 85.0±11.0 | 86.0±31.0 | 49.0±13.0 | NA |
| CRP | 23.3±32.1 | 10.0±40.1 | 6±10.3 | <4 |
| ANCA positive | 92 | 33 | 0 | 0 |
| PR3 positive | 80 | 44 | 0 | 0 |
| MPO positive | 12 | 0 | 0 | 0 |
| BVAS | 4.5±9.0 | 0.0±2.4 | NA | NA |
| VDI | 4.2±0.6 | 3.8±0.8 | NA | NA |
| Bronchiectasis | 30 | 50 | 74¶ | NA |
| Interstitial changes# | 54 | 33 | 100 | NA |
| Cavities | 36 | 17 | 0 | NA |
| Nodules | 82 | 66 | 0 | NA |
| Haemoptysis | 12 | 0 | 0 | NA |
| Steroids | 78 | 77 | 0 | 0 |
| Cyclophosphamide | 43 | 11 | 0 | 0 |
| Azathioprine | 17 | 44 | 0 | 0 |
| Mycophenolate | 9 | 33 | 0 | 0 |
| Methotrexate | 0 | 11 | 0 | 0 |
| Rituximab/infliximab | 9 | 0 | 0 | 0 |
| No medication | 13 | 22 | 0 | 0 |
Data are presented as % or mean±se, unless otherwise stated. GPA: granulomatosis with polyangiitis (Wegener’s); IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; % pred: % predicted; TL,CO: transfer capacity of the lung for carbon monoxide; CRP: C-reactive protein; ANCA: antineutrophil cytoplasmic antibody; PR: proteinase; MPO: myeloperoxidase; BVAS: Birmingham Vasculitis Activity Score; VDI: Vasculitis Damage Index; NA: not applicable. #: included scarring, fibrosis and atelectasis; ¶: traction bronchiectasis.